NEW research, presented at the European Academy of Dermatology and Venereology Congress (EADV) Congress 2024 in Amsterdam, the Netherlands, investigates the efficacy of semaglutide, a GLP-1 receptor agonist, in treating hidradenitis suppurativa (HS), a chronic skin condition prevalent in obese individuals. HS, characterised by painful abscesses and scarring, severely impacts patients’ quality of life. Current treatments are limited and often lead to significant side effects, underscoring the need for new, well-tolerated options.
The study followed 30 patients with obesity and HS (27 females, 3 males, average age 42) from June 2020 to March 2023. Participants received a weekly dose of semaglutide (mean dose 0.8 mg) over an average period of 8.2 months. Researchers tracked changes in body mass index (BMI), weight, flare frequency, pain levels, and quality of life (measured via Dermatology Life Quality Index, DLQI). Biochemical markers such as C-reactive protein (CRP), HbA1c, and glucose were also assessed.
Results indicated a substantial improvement in key health outcomes. The frequency of HS flare-ups decreased from once every 8.5 weeks to once every 12 weeks. Patients reported enhanced quality of life, with DLQI scores dropping from 13 to 9, and one-third of patients achieving a significant DLQI reduction. Additionally, patients experienced weight loss, with the average BMI falling from 43.1 to 41.5 and weight dropping from 117.7 kg to 111.6 kg. One-third lost over 10 kg. There were also improvements in biochemical markers, with HbA1c levels and CRP levels both showing reductions.
Lead researcher Daniel Lyons, St Vincent’s University Hospital, Dublin, Ireland, highlighted that while semaglutide’s weight-loss effects are known, its impact on reducing HS flare-ups is promising. Further randomised trials are recommended to confirm these findings and explore higher doses. This study offers hope for incorporating weight-loss medications into HS treatment strategies.
Abigail Craig, EMJ
Reference
Lyons D et al. Semaglutide for weight loss in obese patients as an adjunctive treatment for hidradenitis suppurative: Its impact on disease control and quality of life. Abstract 4457. EADV Congress 2024, 25-38 September, 2024.
